Navigation Links
New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
Date:5/16/2008

ROCHESTER, Minn., May 16 /PRNewswire-USNewswire/ -- This release is being sent in a social media format, by Mayo Clinic in conjunction with the National Cancer Institute, part of the NIH.

News:

* A new study being presented at the American Society of Clinical Oncology meeting in Chicago (Abstract #4020), may change treatment practice in about 25 percent of patients with colon cancer and is the basis for proposed changes to the way colorectal cancers will be staged.

* This new study, using National Cancer Institute (NCI) SEER population-based statistic registries from 1992 to 2004, and phase III clinical trial data, shows that outcomes of patients with positive nodes (Stage III) in colorectal cancer interact, to a greater extent than previously thought, with how deeply the cancer penetrates the bowel wall.

* Survival outcomes depend on the thickness of the primary cancer within or beyond the bowel wall in addition to whether nodes are positive or negative. A patient with a node positive 'thin' lesion (i.e., confined to the bowel wall) has a stage III cancer with better survival outcomes than a patient with a Stage II node negative 'thick' cancer that penetrates beyond the bowel wall. The current standard of practice for colon cancer patients is that all or most Stage III patients receive chemotherapy after surgical removal of their cancer, but Stage II patients do not routinely receive chemotherapy. In a separate National Cancer Data Base (NCDB) analysis, patients with Stage III colon cancers confined to the bowel wall who did not receive chemotherapy still had better survival than Stage II patients.

* Guidelines for adjuvant therapy may need re-examination in future clinical trials as well as more research into the molecular basis for the interplay between a primary cancer's ability to penetrate the bowel wall and to spread to regional nodes.

* Also, the survival of patients whose cancers invade beyond the bowel wall to involve adjacent structures or organs is worse than that of patients whose cancers merely penetrate to the surface of the bowel wall (the reverse had been thought to be true).

* This abstract/poster will be presented by Dr. Leonard L. Gunderson, M.D., a radiation oncologist from Mayo Clinic, Scottsdale, Ariz., and Vice Chair of the Hindgut Task Force of the American Joint Commission on Cancer (AJCC) that proposes changes to current guidelines. J. Milburn Jessup, M.D., NCI, part of the National Institutes of Health, is the chair of the Task Force.

Quotes:

* J. Milburn Jessup, M.D.: "These proposed changes could lead to real clinical benefit for many colorectal cancer patients and also lessen the amount of treatment that patients with thin lesions may need."

* John E. Niederhuber, M.D., Director, NCI: "Simple advances in treatment that are derived by comparing national statistics to clinical data are greatly welcomed and are an excellent example of moving the field forward by some basic, low-cost methods."

* Leonard L. Gunderson, M.D.: "The current SEER analysis confirms that patients with node positive colon or rectal cancers that do not extend beyond the bowel wall have better survival than previously thought."

Multimedia:

* For still images related to colorectal cancer, go to: http://visualsonline.cancer.gov/details.cfm?imageid=1768; http://visualsonline.cancer.gov/details.cfm?imageid=2345

* For video of chemotherapy and other treatments, go to: http://www.cancer.gov/newscenter/pressreleases/b-roll-treatment.


'/>"/>
SOURCE Mayo Clinic Public Affairs; National Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New method proposed for determining which patients should get treatment for colorectal cancer
2. Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly $43 Million
3. Air Methods Corporation Confirms Fatal Accident in Wisconsin
4. Air Methods Reports 1Q2008 Results and 2Q2008 Update
5. Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
6. New OPAL Therapy presents simple, cost-effective method of treating HIV infection
7. Air Methods to Report First Quarter Financial Results on Thursday, May 8, 2008
8. Determined a new method to establish the antioxidant capacity of extra virgin olive oil
9. Crime Scene Investigation methods could help in the battle against hospital infections
10. Air Methods Provides 1st Quarter Update
11. Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... $3,296 in property taxes a year. In some states—like New York, New Jersey, ... By contrast, many overseas retirement havens have extremely low property-tax rates, which contributes ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: